Related Experiment Videos
Pseudohypoparathyroidism type 1b in pregnancy.
1Department of Obstetrics and Gynecology, Chiba University School of Medicine, Chiba, Japan.
Gynecologic and Obstetric Investigation
|June 3, 1999
Summary
This study monitored calcium-regulating hormones in a patient with pseudohypoparathyroidism type 1b during pregnancy. Treatment with 1alpha-hydroxycalciferol helped maintain near-normal calcium levels throughout gestation.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Mineral Metabolism
Background:
- Pseudohypoparathyroidism type 1b (PHP1b) is a rare genetic disorder affecting calcium homeostasis.
- Pregnancy presents unique challenges for calcium regulation due to increased fetal demand.
- Management of PHP1b during pregnancy requires careful monitoring of calcium-regulating hormones.
Observation:
- Serial measurements of calcium-regulating hormones were performed during the patient's second pregnancy.
- The patient received 1alpha-hydroxycalciferol (2.0 microg daily) for treatment.
- Calcium levels, adjusted for serum albumin, were near normal but showed a slight decrease in late pregnancy.
Findings:
- 1,25-Dihydroxyvitamin D levels were elevated in early and mid-pregnancy compared to postpartum levels.
- Parathyroid hormone levels were higher in late pregnancy than postpartum.
- Treatment with 1alpha-hydroxycalciferol supported adequate calcium levels during pregnancy despite PHP1b.
Implications:
- This case highlights the successful management of pseudohypoparathyroidism type 1b during pregnancy with 1alpha-hydroxycalciferol.
- Findings suggest that careful hormonal monitoring and supplementation can ensure favorable pregnancy outcomes in PHP1b patients.
- Further research into optimal management strategies for PHP1b in pregnancy is warranted.